NQO1 expression correlates with Cholangiocarcinoma prognosis

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue SUPPL.1, 2012, Pages 131-136

  Buranrat, Benjaporn ^a   Chau In, Siri ^a,b   Prawan, Auemduan ^a,b   Puapairoj, Anucha ^a,b   Zeekpudsa, Pornsilp ^a,b   Kukongviriyapan, Veerapol ^a,b  

^a MAHASARAKHAM UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Cytoprotection; Drug metabolizing enzyme antioxidant; NADPH; Quinone oxidoreductase 1

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

BILE DUCT CARCINOMA; BILE DUCT TUMOR; HUMAN; INTRAHEPATIC BILE DUCT; PROGNOSIS;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; HUMANS; NADP; PROGNOSIS;

EID: 84874085253     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.KKSuppl.131     Document Type: Article

References (29)

1. Buranrat B, Prawan A, Kukongviriyapan U, Kongpetch S, Kukongviriyapan V (2010). Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells. World J Gastroenterol, 16, 2362-70.
2. Coussens LM, Werb Z (2002). Inflammation and cancer. Nature, 420, 860-7.
3. Cresteil T, Jaiswal AK (1991). High levels of expression of the NAD(P)H:quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin. Biochem Pharmacol, 42, 1021-7.
4. Danson S, Ward TH, Butler J, Ranson M (2004). DT-diaphorase: a target for new anticancer drugs. Cancer Treat Rev, 30, 437-49.
5. Dijkstra G, Blokzijl H, Bok L, et al (2004). Opposite effect of oxidative stress on inducible nitric oxide synthase and haem oxygenase-1 expression in intestinal inflammation: anti-inflammatory effect of carbon monoxide. J Pathol, 204, 296-303.
6. Green A, Uttaravichien T, Bhudhisawasdi V, et al (1991). Cholangiocarcinoma in north east Thailand. A hospital-based study. Trop Geogr Med, 43, 193-8.
7. Guglielmi A, Ruzzenente A, Campagnaro T, et al (2009). Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. World J Surg, 33, 1247-54.
8. IARC (1994). Infection with liver flukes (Opisthorchis viverrini, Opisthorchis felineus and Clonorchis sinensis). IARC Monogr Eval Carcinog Risks Hum, 61, 121-75.
9. Jinawath N, Chamgramol Y, Furukawa Y, et al (2006). Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma. Hepatology, 44, 1025-38.
10. Kamsa-ard S, Wiangnon S, Suwanrungruang K, et al (2011). Trends in liver cancer incidence between 1985 and 2009, Khon Kaen, Thailand: cholangiocarcinoma. Asian Pac J Cancer Prev, 12, 2209-13.
11. Kensler TW, Wakabayashi N (2010). Nrf2: friend or foe for chemoprevention? Carcinogenesis, 31, 90-9.
12. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD (2005). Cholangiocarcinoma. Lancet, 366, 1303-14.
13. Kolesar JM, Pritchard SC, Kerr KM, et al (2002). Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. Int J Oncol, 21, 1119-24.
14. Logsdon CD, Simeone DM, Binkley C, et al (2003). Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res, 63, 2649-57.
15. Ohshima H, Tazawa H, Sylla BS, Sawa T (2005). Prevention of human cancer by modulation of chronic inflammatory processes. Mutat Res, 591, 110-22.
16. Patel T (2011). Cholangiocarcinoma--controversies and challenges. Nat Rev Gastroenterol Hepatol, 8, 189-200.
17. Pinlaor S, Hiraku Y, Ma N, et al (2004). Mechanism of NO-mediated oxidative and nitrative DNA damage in hamsters infected with Opisthorchis viverrini: a model of inflammation-mediated carcinogenesis. Nitric Oxide, 11, 175-83.
18. Prawan A, Buranrat B, Kukongviriyapan U, Sripa B, Kukongviriyapan V (2009). Inflammatory cytokines suppress NAD(P)H:quinone oxidoreductase-1 and induce oxidative stress in cholangiocarcinoma cells. J Cancer Res Clin Oncol, 135, 515-22.
19. Prochaska HJ, Santamaria AB (1988). Direct measurement of NAD(P)H:quinone reductase from cells cultured in microtiter wells: a screening assay for anticarcinogenic enzyme inducers. Anal Biochem, 169, 328-36.
20. Radjendirane V, Joseph P, Lee YH, et al (1998). Disruption of the DT diaphorase (NQO1) gene in mice leads to increased menadione toxicity. J Biol Chem, 273, 7382-9.
21. Saldivar SJ, Wang Y, Zhao H, et al (2005). An association between a NQO1 genetic polymorphism and risk of lung cancer. Mutat Res, 582, 71-8.
22. Siegel D, Gustafson DL, Dehn DL, et al (2004). NAD(P) H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol Pharmacol, 65, 1238-47.
23. Siegel D, Ross D (2000). Immunodetection of NAD(P) H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med, 29, 246-53.
24. Sripa B, Pairojkul C (2008). Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol, 24, 349-56.
25. Strassburg A, Strassburg CP, Manns MP, Tukey RH (2002). Differential gene expression of NAD(P)H:quinone oxidoreductase and NRH:quinone oxidoreductase in human hepatocellular and biliary tissue. Mol Pharmacol, 61, 320-5.
26. Subimerb C, Pinlaor S, Khuntikeo N, et al (2010). Tissue invasive macrophage density is correlated with prognosis in cholangiocarcinoma. Mol Med Report, 3, 597-605.
27. Surh YJ, Kundu JK, Na HK (2008). Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med, 74, 1526-39.
28. Wakai T, Shirai Y, Sakata J, et al (2011). Prognostic significance of NQO1 expression in intrahepatic cholangiocarcinoma. Int J Clin Exp Pathol, 4, 363-70.
29. Yang FY, Guan QK, Cui YH, et al (2012). NAD(P)H quinone oxidoreductase 1 (NQO1) genetic C609T polymorphism is associated with the risk of digestive tract cancer: a metaanalysis based on 21 case-control studies. Eur J Cancer Prev, 21, 432-41.